METHODS: This study was conducted based on the PRISMA 2020 criteria. Initial searching was conducted using MeSH (Medical Subject Headings)-based keywords with no time limitation (by August 1, 2024). Collected papers were transferred to Citation Management Software (EndNote). Duplicate studies were merged and primary and secondary screenings were applied based on the inclusion/exclusion criteria. Validation was considered to find high-quality assessments. Finally, eligible extractable papers were enrolled for data collection. Data was analyzed using Comprehensive Meta-Analysis software (v.2) The random effects model was used in case of I2 index above 50%.In order to investigate the factors affecting the heterogeneity of studies, meta-regression tests were used to examine factors such as sample size and year of study.
RESULTS: One hundred thirty-eight eligible studies with a total sample size of 135,098 pregnant women individuals were selected for data extraction and analysis. The heterogeneity index was found high (I2:98.9) and the random effect model was used for analysis. The egger test revealed the absence of publication bias in collected studies (p:0.088). Thus, the global seroprevalence of Toxoplasma gondii in pregnant women was reported at 36.6% (95%CI:33.7-39.6). the highest prevalence reported based on meta-analysis was reported in South America with 52.8% (95% CI:46.6-59), while only 15 studies were reviewed in this continent, most of which were in Brazil. Therefore, after the continent, the highest prevalence reported was reported in Africa with 46.8% (95% CI:39.5-54.3). Also, the lowest prevalence reported based on meta-analysis was in North America with 19.7% (95% CI:8.4-39.6) and Europe with 24.6% (95% CI:17.8-32.9).
CONCLUSION: This study revealed a high level of seroprevalence of Toxoplasma gondii in pregnant women worldwide. This value mostly depends on the individual's age, lifestyle, and disease awareness regarding toxoplasmosis in pregnant women. Thus, public awareness, along with comprehensive health programs regarding the detrimental effects of toxoplasmosis in pregnant women, seems necessary for prevention or even early diagnosis of toxoplasmosis in pregnant women.
OBJECTIVE: This study explores the factors, characteristics, and effects of MAP changes caused by KOA, providing a neuromuscular-based causal analysis for the rehabilitation treatment of KOA.
METHODS: Keywords including the association of MAP with KOA will be included. "Knee, Osteoarthritis, Electromyography(EMG), Muscle Activity patterns, activation amplitudes, activation time, Muscle Synergy, Co-contraction/activation" were used to search the databases of Science Direct, PubMed, Scopus, and Wiley. The criteria include studies from the past fifteen years that document changes in muscle contraction characteristics and causality analysis in patients with KOA. we compared MAP changes between individuals with and without KOA, such as the activation amplitudes, activation time, muscle synergy and co-contraction index(CCI). Additionally, we explored the potential relationship between muscle weakness, pain, and lower limb mechanical changes with the variations of MAP.
RESULTS: A total of 832 articles were reviewed, and 44 articles that met the inclusion criteria were selected for analysis. The changes in biomechanical structure, pain, and muscle atrophy may contribute to the formation and progression of the changes in MAP in KOA patients. In moderate KOA patients, the vastus lateralis (VL) and biceps femoris (BF) exhibits larger activation amplitudes, with earlier and longer activation times. The vastus medialis (VM) shows a delayed activation time relative to VL. Gastrocnemius activation time is prolonged during mid-gait, while the soleus exhibits lower activation amplitudes during the late stance phase. There are fewer, merged synergies with prolonged activation coefficients, and a higher percentage of unclassifiable synergies. Additionally, the CCI is positively correlated with task difficulty and symptoms. It is higher in the medial and lateral than hamstrings and quadriceps, and CCI specifically respond to joint stabilisation and load.
CONCLUSION: In patients with moderate KOA, changes in MAP are mainly related to symptoms and the difficulty of tasks. MAP changes primarily result in variations in amplitude, contraction duration, muscle synergy, and CCI. The MAP changes can subsequently affect the intermuscular structure, pain, joint loading, and stiffness.
CLINICAL IMPLICATIONS: These contribute to the progression of KOA and create a vicious cycle that accelerates disease advancement. Clinical rehabilitation treatments can target the MAP changes to break the cycle and help mitigate disease progression.
METHOD: We undertook a comprehensive literature search across 5 electronic databases (PubMed, Scopus, Web of Science, The Cochrane Library, clinicaltrials.gov, and EMBASE) from inception through February 2024. Three reviewers screened all randomized controlled trials (RCTs) and assessed quality, and two reviewers extracted data. The meta-analysis used standardized mean difference (SMD) with Hedges' g method, a random effects model adjusted by Hartung-Knapp, and assessed heterogeneity (I² statistic), weighted studies (inverse variance), and evaluated publication bias (Begg's funnel plot and linear regression test).
RESULT: We located 13 RCTs for inclusion in the meta-analysis. Tele-exercise interventions demonstrated significant improvements across all outcomes: depression (SMD=-0.51, p < 0.001), fatigue (SMD=-0.58, p = 0.01), physical health (SMD=0.62, p = 0.001), QoL (SMD=0.38, p = 0.02), and mental health (SMD=-0.48, p = 0.001). Mind-Body Training consistently had larger effects than Combination Training.
CONCLUSION: Tele-exercise can improve fatigue, depression, mental and physical health, and overall QoL in MS patients. Further research is necessary to optimize tele-exercise protocols, assess long-term effects, and explore potential synergies with other intervention modalities such as telemedicine.
METHODS: This study was carried out in urban and rural communities with adults aged between 35 and 70 years using purposive sampling. Standardized questionnaires were used to assess the smoking status and sociodemographic data of the participants. Bivariate analysis and multiple logistic regression were done to determine the association between smoking status and demographic characteristics among Malaysian adults.
RESULTS: The prevalence of smoking among adults is 23.2%. The sociodemographic factors significantly associated with active smoking status were being a younger adult (adjusted odds ratio [AOR] = 1.26, 95% CI: 1.06-1.50), being male (AOR = 24.16, 95% CI: 20.58-28.36), being Malay (AOR = 1.72, 95% CI: 1.49-1.98), being a blue-collar worker (AOR = 1.75, 95% CI: 1.48-2.06), having no formal education (AOR = 1.99, 95% CI: 1.56-2.53), being unmarried (AOR = 1.22, 95% CI: 1.02-1.48) and being of low socioeconomic status (AOR = 1.45, 95% CI: 1.14-1.84).
CONCLUSION: Public health policies and actions on smoking reduction should emphasize those identified as high-risk sub-populations, particularly younger adults, males and those who are not yet married, have no formal education and are of low socioeconomic status.
METHODS: In 35,815 patients from the VISION cohort study and 9219 patients from the POISE-2 trial who were ≥45 yr old and underwent nonurgent inpatient noncardiac surgery, we examined (by age and sex) the association between continuous nonlinear preoperative estimated glomerular filtration rate (eGFR) and the composite of myocardial injury after noncardiac surgery, nonfatal cardiac arrest, or death owing to a cardiac cause within 30 days after surgery. We estimated contributions of predictive information, C-statistic, and net benefit from eGFR and other common patient and surgical characteristics to large multivariable models.
RESULTS: The primary composite occurred in 4725 (13.2%) patients in VISION and 1903 (20.6%) in POISE-2; in both studies cardiac events had a strong, graded association with lower preoperative eGFR that was attenuated by older age (Pinteraction<0.001 for VISION; Pinteraction=0.008 for POISE-2). For eGFR of 30 compared with 90 ml min-1 1.73 m-2, relative risk was 1.49 (95% confidence interval 1.26-1.78) at age 80 yr but 4.50 (2.84-7.13) at age 50 yr in female patients in VISION. This differed modestly (but not meaningfully) in men in VISION (Pinteraction=0.02) but not in POISE-2 (Pinteraction=0.79). eGFR contributed the most predictive information and mean net benefit of all predictors in both studies, most C-statistic in VISION, and third most C-statistic in POISE-2.
CONCLUSIONS: Continuous preoperative eGFR is among the best cardiac risk predictors in noncardiac surgery of the large set examined. Along with its interaction with age, preoperative eGFR would improve risk calculators.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT00512109 (VISION) and NCT01082874 (POISE-2).
METHOD: The phospholipid nanocarrier dispersion showed significantly enhanced in-vitro release, porcine skin/ intestine permeation, and retention. When the ratio of the MGR versus partially hydrogenated ginsenoside reached 1:1 w/w in the nanocarrier composition, the in-vitro release increased 54.8-fold compared to the MGR powder suspended in the release media.
RESULTS: Permeation of the nanocarrier dispersion through the porcine skin and intestine increased 160-fold and 42-fold, respectively, compared to permeation of the MGR powder suspension. Furthermore, the nanocarrier dispersion reduced NO production and iNOS mRNA expression in the LPS-stimulated RAW264.7 cells. MIC and MBC of the nanocarrier dispersion against P. gingivalis were 4.11 ± 1.17 and 8.22 ± 2.35 μg/mL, respectively.
CONCLUSION: In conclusion, the anti-inflammatory and antibacterial activities of MGR were remarkably enhanced when the MGR was loaded into the nanocarrier with partially hydrolyzed ginsenoside.
METHODS: We collected responses to an online and physical survey from people living with T2D through a quantitative cross-sectional study. First, we tested the contextual validity and cultural preciseness of ASQ-DM-EX prototype through a preliminary pilot testing phase. These processes culminated in the development of a 91-item version of the questionnaire which was disseminated widely to evaluate the predictive strength of the ASQ-DM-EX.
RESULTS: All constructs within ASQ-DM-EX showed internal consistencies within good to excellent range (Cronbach's ⍺ = 0.70-0.94), except for the Influence construct (Cronbach's ⍺ = 0.33). An increase in ASQ-DM-EX scores was associated with a reduction in HbA1c control (r = -0.17, P
METHODS: Melt emulsification followed by ultrasonication was used as a method of preparation and Quality-by-Design (QbD) was utilized to optimize ABE-SLNs.
RESULTS: The optimized ABE-SLNs consist of Precirol-ATO5 as a lipid and Brij-58 as a surfactant. The particle size, PDI value, and zeta potential of the optimized formulation were 170.4 ± 0.49 nm, 0.25 ± 0.014, and -26.4 ± 0.1 mV, respectively. It also showed sustained release behavior and a high entrapment efficiency of 79.96%. ABE-SLNs exhibited enhanced anticancer activity in the MDA-MB-231 and T47D breast cancer cell lines compared to pure ABE. In Caco-2 human colonic cell lines, ABE-SLNs also showed increased cellular uptake.
CONCLUSION: The use of QbD to achieve high entrapment efficiency and sustained release in ABE-SLNs, coupled with enhanced cellular uptake and cytotoxicity, represents a novel approach that could set a new standard for nanoparticle-based drug delivery systems.